Inhibitory potency of Valsartan/Sacubitril drug combination: molecular docking simulations

被引:0
|
作者
Jovanovic, Jelena Dorovic [1 ,2 ]
Markovic, Zoran [2 ]
Kokanovic, Mihajlo [1 ]
Filipovic, Nenad [3 ]
Stanojevic, Ma Rijana [4 ]
机构
[1] Bioengn Res & Dev Ctr BioIRC, Kragujevac, Serbia
[2] Univ Kragujevac, Inst Informat Technol, Dept Sci, Kragujevac 34000, Serbia
[3] Univ Kragujevac, Fac Engn, Bioengn Res & Dev Ctr, Kragujevac, Serbia
[4] Univ Kragujevac, Fac Med Sci, Pirkov Dept Biochem, Kragujevac 34000, Serbia
基金
欧盟地平线“2020”;
关键词
Entresto; molecular docking simulations; Neprilysin; Angiotensin II receptor;
D O I
10.1109/BIBE52308.2021.9635185
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Heart failure (HF) is a condition that affects mostly older populations. It can be treated with different medications, and one of them is Entresto. This is a medication which is consisting of two drugs, sacubitril (SAC) and valsartan (VAL). Here, in this study, are performed molecular docking simulations in order to examine the inhibitory potency of SAC and VAL towards neprilysin (NEP) and angiotensin II receptor (AT2), respectively. The achieved thermodynamic parameters shows that SAC and VAL can bind to targeted protein, and inhibit NEP and AT2. The best binding sites are determined. Also, the amino acids responsible for binding are identified.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?
    Yang CHEN
    LuYing GUO
    LingFei ZHAO
    YanHong MA
    XueLing ZHU
    Ying XU
    JiangHua CHEN
    Journal of Geriatric Cardiology, 2020, 17 (12) : 782 - 786
  • [42] Evaluation of Metabolic Enzyme Inhibitory Potency with Molecular Docking Assisted Studies: Phenolic Compound Analysis of Seseli resinosum
    Kaya, Zafer
    Imamoglu, Rizvan
    Ceylan, Kevser Betul
    Genc, Nusret
    Kisa, Dursun
    JOURNAL OF BIOLOGICALLY ACTIVE PRODUCTS FROM NATURE, 2023, 13 (01) : 49 - 67
  • [43] Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Greene, Stephen J.
    Aggarwal, Rahul
    Bhatt, Ankeet S.
    McMurray, John J. V.
    Fonarow, Gregg C.
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2021, 6 (12) : 1415 - 1423
  • [44] Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?
    Chen, Yang
    Guo, Lu-Ying
    Zhao, Ling-Fei
    Ma, Yan-Hong
    Zhu, Xue-Ling
    Xu, Ying
    Chen, Jiang-Hua
    JOURNAL OF GERIATRIC CARDIOLOGY, 2020, 17 (12) : 782 - 786
  • [46] Valsartan and sacubitril combination treatment enhances collagen production in older adult human skin cells
    Marin, Sela
    Godet, Ines
    Nidadavolu, Lolita S.
    Tian, Jing
    Dickinson, Laura E.
    Walston, Jeremy D.
    Gilkes, Daniele M.
    Abadir, Peter M.
    EXPERIMENTAL GERONTOLOGY, 2022, 165
  • [47] Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date
    Vilela-Martin, Jose Fernando
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1627 - 1639
  • [48] VALSARTAN AND SACUBITRIL COMBINATION TREATMENT ENHANCES COLLAGEN PRODUCTION IN OLDER ADULT HUMAN SKIN CELLS
    Marin, Sela
    Godet, Ines
    Nidadavolu, Lolita S.
    Walston, Jeremy
    Gilkes, Daniele
    Abadir, Peter M.
    INNOVATION IN AGING, 2021, 5 : 684 - 684
  • [49] Investigation of angiotensin-I-converting enzyme (ACE) inhibitory tri-peptides: a combination of 3D-QSAR and molecular docking simulations
    Wang, Fangfang
    Zhou, Bo
    RSC ADVANCES, 2020, 10 (59) : 35811 - 35819
  • [50] Sacubitril/valsartan in Heart Failure and Beyond-From Molecular Mechanisms to Clinical Relevance
    Nikolic, Maja
    Srejovic, Ivan
    Jovic, Jovana Joksimovic
    Sretenovic, Jasmina
    Jeremic, Jovana
    Cekerevac, Ivan
    Simovic, Stefan
    Djokovic, Danijela
    Muric, Nemanja
    Stojic, Vladislava
    Bolevich, Stefani
    Bolevich, Sergey
    Jakovljevic, Vladimir
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (07)